Pfizer Inc (PFE) - Total Liabilities
Based on the latest financial reports, Pfizer Inc (PFE) has total liabilities worth $117.21 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Pfizer Inc growing its equity to track the company's year-over-year net asset growth rate.
Pfizer Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Pfizer Inc's total liabilities have evolved over time, based on quarterly financial data. See PFE free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Pfizer Inc Competitors by Total Liabilities
The table below lists competitors of Pfizer Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Welltower Inc
NYSE:WELL
|
USA | $22.29 Billion |
|
Shopify Inc
TO:SHOP
|
Canada | CA$1.62 Billion |
|
Uber Technologies Inc
NYSE:UBER
|
USA | $33.72 Billion |
|
Salesforce.com Inc
NYSE:CRM
|
USA | $72.44 Billion |
|
ALLIANZ SE UNSP.ADR 1/10
F:ALVE
|
Germany | €957.93 Billion |
|
ConocoPhillips
NYSE:COP
|
USA | $58.18 Billion |
|
Allianz SE VNA O.N.
XETRA:ALV
|
Germany | €949.07 Billion |
|
Airbus SE
F:AIRA
|
Germany | €112.52 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Pfizer Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PFE stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pfizer Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pfizer Inc (1985–2025)
The table below shows the annual total liabilities of Pfizer Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $121.39 Billion | -2.81% |
| 2024-12-31 | $124.90 Billion | -8.97% |
| 2023-12-31 | $137.21 Billion | +35.47% |
| 2022-12-31 | $101.29 Billion | -2.62% |
| 2021-12-31 | $104.01 Billion | +14.61% |
| 2020-12-31 | $90.76 Billion | -12.77% |
| 2019-12-31 | $104.04 Billion | +8.76% |
| 2018-12-31 | $95.66 Billion | -4.47% |
| 2017-12-31 | $100.14 Billion | -10.41% |
| 2016-12-31 | $111.78 Billion | +9.09% |
| 2015-12-31 | $102.46 Billion | +4.93% |
| 2014-12-31 | $97.65 Billion | +2.27% |
| 2013-12-31 | $95.48 Billion | -8.30% |
| 2012-12-31 | $104.12 Billion | -1.20% |
| 2011-12-31 | $105.38 Billion | -1.28% |
| 2010-12-31 | $106.75 Billion | -12.86% |
| 2009-12-31 | $122.50 Billion | +129.37% |
| 2008-12-31 | $53.41 Billion | +6.51% |
| 2007-12-31 | $50.14 Billion | +13.67% |
| 2006-12-31 | $44.11 Billion | -13.85% |
| 2005-12-31 | $51.21 Billion | -6.56% |
| 2004-12-31 | $54.80 Billion | +6.62% |
| 2003-12-31 | $51.40 Billion | +94.65% |
| 2002-12-31 | $26.41 Billion | +26.59% |
| 2001-12-31 | $20.86 Billion | +19.65% |
| 2000-12-31 | $17.43 Billion | +0.07% |
| 1999-12-31 | $17.42 Billion | +83.54% |
| 1998-12-31 | $9.49 Billion | +34.49% |
| 1997-12-31 | $7.06 Billion | -7.90% |
| 1996-12-31 | $7.66 Billion | +6.79% |
| 1995-12-31 | $7.18 Billion | +6.54% |
| 1994-12-31 | $6.74 Billion | +24.14% |
| 1993-12-31 | $5.43 Billion | +12.19% |
| 1992-12-31 | $4.84 Billion | +5.74% |
| 1991-12-31 | $4.57 Billion | +16.35% |
| 1990-12-31 | $3.93 Billion | +4.42% |
| 1989-12-31 | $3.76 Billion | +12.84% |
| 1988-12-31 | $3.34 Billion | +9.75% |
| 1987-12-31 | $3.04 Billion | +73.88% |
| 1986-12-31 | $1.75 Billion | +13.86% |
| 1985-12-31 | $1.54 Billion | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more